A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Study Evaluating KTE-C19 in Subjects With Acute Lymphoblastic Leukemia or B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Sponsor: KITE Pharma
Enrolling: Male and Female Patients
Study Length: 15 Years
Clinic Visits: 40
IRB Number: AAAS3695
U.S. Govt. ID: NCT02625480
Contact: Dylan Stein: 212-345-9770 / djs2245@cumc.columbia.edu
Additional Study Information: The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma.
This study is closed
Investigator
Prakash Satwani, MD
Do You Qualify?
Do you or your child have leukemia or Non-Hodgkin Lymphoma? Yes No
Do you or your child have measurable disease in the Bone Marrow? Yes No
Is CD19 tumor expression on blasts after your/your child's most recent completion of therapy? Yes No
Do you/ your child have any fungal, bacterial, viral or other infection that is uncontrolled or requiring IV microbials? Yes No
Are you/your child taking corticosteroid therapy at a does of or = to 0.7 mg/kg/day? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Dylan Stein
djs2245@cumc.columbia.edu
212-345-9770